ClinicalTrials.gg
CompletedNCT06469164Updated Oct 5, 2026Results posted

A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis

A Phase 1 interventional study of BNT331 and Placebo in Bacterial Vaginosis, sponsored by BioNTech SE. Completed at 6 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by BioNTech SE · Phase 1, Interventional, and Treatment

How we know

Updated Oct 5, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Vaginosis, Bacterial with a site in United States — 8 open to participants now, 8 under way, none of them phase 3. Vaginosis, Bacterial · United States.

Enrollment
31st of 69
102 · median 81
Started
2024
with 7 others
Phase 1
12 of 82
1 open now
Registered
74th of 82
by date

Among the 82 studies in Vaginosis, Bacterial with a site in United States, this one is the 31st largest by enrollment of the 69 interventional ones that give a count, is one of 8 that started in 2024, is one of 12 in phase 1, and was the 74th registered.

Vaginosis, Bacterial

240 studies on the registry are indexed under Vaginosis, Bacterial; 39 are open to participants now.

Browse Vaginosis, Bacterial studies →

Open to participants now

8 of the 82 studies in Vaginosis, Bacterial with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Vaginosis, Bacterial studies recruiting now, 7 (30%) set no upper age limit and 16 (70%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Vaginosis, Bacterial with a site in United States, or all of them as a file.
02

Study summary

This was a two-part, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy (for Part B) of BNT331 in healthy women (Part A) and in women diagnosed with bacterial vaginosis (BV) (Part B).

Read the detailed description

Part A included single ascending dose levels and assessed the safety of BNT331 and described the incidence of adverse events (AEs) for participants randomized at a ratio of 3:1 to BNT331 or placebo. Participants received one single dose of study treatment.

Part B included multiple ascending dose levels. Participants were randomized at a ratio of 2:1 to BNT331 or placebo. Participants with BV received study treatment for five consecutive days.

The vaginal inserts were self-administered by the participant. The participants received detailed instructions from the investigator on how to self-administer the vaginal inserts at home.

03

Conditions studied

  • Bacterial Vaginosis

Browse trials for

Keywords

  • Gardnerella spp.
  • Gardnerella vaginalis
  • BNT331
04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria (applicable to all participants unless otherwise specified):

  • Had given written by signing and dating the informed consent form (ICF) before initiation of any study-specific procedures.
  • Participant reported assigned female sex at birth, at least 18 years of age and pre-menopausal, as determined by the investigator.
  • Not menstruating or having vaginal bleeding:

    • Part A: At Visit 0 and not expected to menstruate during Visit 1 and until Visit 3.
    • Part B only: At Visit 0 and Visit 1 and not expected to menstruate within the next 6 days after Visit 1, until the Early Response Visit (Visit 2).
  • Part A only: Were healthy according to screening procedures. Part B only: Participants suffering from BV but who were otherwise healthy in the clinical judgement of the investigator.

    • Note: Participants with pre-existing stable disease (e.g., obesity, hypertension, etc.), defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 90 days before Visit 0, were included.
  • Part A only: Should not have any clinical signs of BV as assessed by the absence of all Amsel's criteria and a normal Nugent score at screening, or other vaginal symptoms, including symptomatic vulvo-vaginal candidiasis (VVC) or infection with sexually transmitted infection (STI) pathogens including Chlamydia trachomatis, Trichomonas vaginalis, or Neisseria gonorrhoeae.
  • Able to participate in the study as an outpatient, to attend all required visits, and to comply with all study requirements.
  • Women of must have a negative highly sensitive urine pregnancy test result prior to study treatment initiation.
  • The participant must have been on the same form of highly effective for at least 3 months prior to dosing (Visit 1) and must agree to keep this method until:

    • Part A: 60 days after Follow-up Visit (Visit 3)
    • Part B: at least 60 days after Test of Cure (ToC) Visit (Visit 3).
  • Women of childbearing potential who agree not to donate or cryopreserve eggs (ova, oocytes) for the purposes of assisted reproduction during study:

    • Part A: Within 3 months prior to dosing (Visit 1) and continuously until 60 days after Follow-up Visit (Visit 3)
    • Part B: Starting at Visit 0 and continuously until the Late Follow-up Visit (Visit 5).
  • Agree to abstain from vaginal intercourse:

    • Part A: From 72 hours prior to dosing until the Follow-up Visit (Visit 3)
    • Part B: For the duration of treatment (\~5 days) and until ToC Visit (Visit 3).
  • Agree to not use any vaginal products, e.g., creams, gels, foams, sponges, douches, and tampons (except during menstruation):

    • Part A: From 72 hours prior to dosing until the Follow-up Visit (Visit 3)
    • Part B: Until ToC Visit (Visit 3).
  • Part B only: Have a clinical diagnosis of BV, defined as having all the following Amsel's criteria (4/4):

    1. Off-white (milky or gray), thin, homogeneous vaginal discharge.
    2. Vaginal pH >4.5.
    3. Presence of clue cells ≥20% of the total epithelial cells/high power field on microscopic examination of the vaginal saline wet mount.
    4. A positive 10% potassium hydroxide (KOH) Whiff test.
  • Part B only: Have a sample collected within 72 h prior to first dose for a Gram stain slide to assess Nugent score by the central laboratory.

Exclusion Criteria (applicable to all participants unless otherwise specified):

  • Pregnant, lactating, or planning to become pregnant during their study participation and for at least:

    • Part A: 60 days after Follow-up Visit (Visit 3)
    • Part B: 60 days after ToC Visit (Visit 3).
  • Had genital lesions, including active herpes simplex virus or syphilitic lesions, or other vaginal or vulvar conditions.
  • Part A only: Had active STI.
  • Had received antifungal or antimicrobial therapy (in Part A, systemic or topical; in Part B, systemic or vaginal) within 14 days prior to the Visit 1.
  • Were using a Copper intrauterine device, or any vaginal hormonal products (including NuvaRing®) as a form of contraception.
  • Had a history of drug or alcohol abuse within the past 12 months, as determined by the investigator.
  • Had participated in any study within 30 days before the Visit 1 or is currently participating or plans to participate in any investigational, or observational study.
  • Had any history of allergies, , or intolerance to the study treatments including any thereof.
  • Had any history of an abnormal Pap smear which required cervical and/or cervical cauterization within 6 months of Visit 1.
  • within 5 years of screening, including but not limited to cervical carcinoma and carcinomas of the vagina and vulva.
  • Had any condition including psychiatric illnesses that could interfere with their ability to understand or comply with the requirements of the study as determined by the investigator.
  • Vulnerable individuals, i.e., were individuals whose willingness to participate in a clinical study was unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate. This includes all sponsor, study site, or third party (e.g., Clinical Research Organization, vendor) personnel directly involved in the conduct of the study and their family members or dependents, as well as all study site personnel otherwise supervised by the investigator.
  • Part B only: Currently suspected clinically (or confirmed diagnostically) of having alternative causes of vaginal disease symptoms including symptomatic VVC or infection with STI including Chlamydia trachomatis, Trichomonas vaginalis, or Neisseria gonorrhoeae.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
102 participants (actual)

Study arms

  • Placebo comparator
    Part A: Placebo (Combined for Cohorts 1, 2 and 3)

    Healthy participants received a single dose of placebo administered as a vaginal insert on Day 1.

    Other: Placebo

  • Experimental
    Part A: Cohort 1: BNT331 2 Milligram (mg)

    Healthy participants received a single 2 mg dose of BNT331 administered as a vaginal insert on Day 1.

    Drug: BNT331

  • Experimental
    Part A: Cohort 2: BNT331 5 mg

    Healthy participants received a single 5 mg dose of BNT331 administered as a vaginal insert on Day 1.

    Drug: BNT331

  • Experimental
    Part A: Cohort 3: BNT331 20 mg

    Healthy participants received a single 20 mg dose of BNT331 administered as a vaginal insert on Day 1.

    Drug: BNT331

  • Placebo comparator
    Part B: Placebo (Combined for Cohorts 4 and 5)

    Participants diagnosed with bacterial vaginosis received placebo as a vaginal insert once daily for five consecutive days.

    Other: Placebo

  • Experimental
    Part B: Cohort 4: BNT331 5 mg

    .Participants diagnosed with bacterial vaginosis received 5 mg dose of BNT331 as a vaginal insert once daily for five consecutive days.

    Drug: BNT331

  • Experimental
    Part B: Cohort 5: BNT331 20 mg

    Participants diagnosed with bacterial vaginosis received 20 mg dose of BNT331 as a vaginal insert once daily for five consecutive days.

    Drug: BNT331

Interventions

  • DrugBNT331

    Vaginal insert

  • OtherPlacebo

    Vaginal insert

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Any Serious TEAE

    Treatment-emergent adverse events (TEAEs) are those Adverse Events with an onset on or after the date and time of study treatment or events which were present before treatment, and which worsened after treatment. Serious adverse event (SAE): any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect or was another medically important condition.

    Time frame: Up to 7 days post dose on Day 1

  2. Part B: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Any Serious TEAE

    Treatment-emergent adverse events are those AEs with an onset on or after the date and time of study treatment or events which were present before treatment, and which worsened after treatment. Serious adverse event (SAE): any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect or was another medically important condition. AE were graded for severity using NCI-CTCAE v5.0, where Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4 - Life-threatening consequences; and Grade 5: Death related to AE.

    Time frame: Up to 120 days after first dose on Day 1

Secondary outcomes

  1. Part A: Serum Concentrations of BNT331 Active Substance

    Blood samples were collected to determine the serum concentrations of BNT331 active substance. Geometric Mean and geometric coefficient of variation (GCV) data were reported for the outcome measure.

    Time frame: Pre-dose, 1 hour, 2 hours, 4 hours, 6 hours, 24 hours and 7 days post-dose on Day 1

  2. Part B: Serum Concentrations of BNT331 Active Substance

    Blood samples were collected to determine the serum concentrations of BNT331 active substance. Geometric Mean and coefficient of variation data were reported for the outcome measure.

    Time frame: Pre-dose, At Visit 2 (i.e. Day 6 post dose on Day 1) and at Visit 3 (i.e., Days 21 to 30 post-dose on Day 1)

  3. Part A: Number of Participants With Qualitative Anti-drug Antibody (ADA) for BNT331 Active Substance in Blood

    ADA-positive samples were defined as a sample confirmed to be positive for the presence of reactive antibodies. Positive qualitative ADA for BNT331 active substance in blood were reported in the outcome measure.

    Time frame: At Pre-dose (Baseline), at 7 days post-dose on Day 1

  4. Part B: Number of Participants With Qualitative Anti-drug Antibody (ADA) for BNT331 Active Substance in Blood

    ADA-positive samples were defined as a sample confirmed to be positive for the presence of reactive antibodies. Positive qualitative ADAs for BNT331 active substance in blood were reported in the outcome measure.

    Time frame: At Pre-dose (Baseline), 6 days after the first dose on Day 1, 21 to 30 days after the first dose on Day 1, and 60 days after the first dose on Day 1

  5. Part B - Number of Participants With Clinical Cure

    Clinical cure was defined as normalization of the vaginal discharge, a negative KOH "Whiff" test, and clue cells \<20% of the total epithelial cells/high power field on microscopic examination of the vaginal fluid. Data for this outcome measure was not planned to be collected and analyzed for Part A.

    Time frame: At 6 days after first dose on Day 1; and 21 to 30 days after the first dose on Day 1

  6. Part B: Number of Participants With Nugent Score Cure/Microbiological Cure

    Nugent score cure/Microbiological cure was defined as a score of \<4. A Nugent score of 7-10 is indicative of BV, while a score of 4 to 6 is considered intermediate vaginal microbiota and a score of 0 to 3 is considered normal vaginal microbiota. Data for this outcome measure was not planned to be collected and analyzed for Part A.

    Time frame: At 6 days after first dose on Day 1; and 21 to 30 days after the first dose on Day 1

  7. Part B: Number of Participants (Responders Outcome) Reporting Clinical Cure With a Normal Nugent Score of Less Than (<) 4

    Responder outcome was defined as an occurrence of clinical cure with a normal Nugent score (\<4). A Nugent score of 7-10 is indicative of BV, while a score of 4 to 6 is considered intermediate vaginal microbiota and a score of 0 to 3 is considered normal vaginal microbiota. Data for this outcome measure was not planned to be collected and analyzed for Part A.

    Time frame: At 6 days after first dose on Day 1; and 21 to 30 days after the first dose on Day 1

07

Results

Posted Oct 5, 2026

Participant flow

Participant flow — Overall Study
MilestonePart A: Placebo (Combined for Cohorts 1, 2 and 3)Part A: Cohort 1: BNT331 2 Milligram (mg)Part A: Cohort 2: BNT331 5 mgPart A: Cohort 3: BNT331 20 mgPart B: Placebo (Combined for Cohorts 4 and 5)Part B: Cohort 4: BNT331 5 mgPart B: Cohort 5: BNT331 20 mg
Started6666262626
Safety analysis set6666252523
Completed6666202420
Not completed0000626
Withdrew: Withdrawal by subject0000313
Withdrew: Lost to follow-up0000112
Withdrew: Protocol violation0000101
Withdrew: Other-unspecified0000100

Outcome measures

PrimaryPart A: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Any Serious TEAE

Treatment-emergent adverse events (TEAEs) are those Adverse Events with an onset on or after the date and time of study treatment or events which were present before treatment, and which worsened after treatment. Serious adverse event (SAE): any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect or was another medically important condition.

Time frame:
Up to 7 days post dose on Day 1
Reported as:
Count of participants · Participants
Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Any Serious TEAE
ParticipantsPart A: Placebo (Combined for Cohorts 1, 2 and 3)Part A: Cohort 1: BNT331 2 Milligram (mg)Part A: Cohort 2: BNT331 5 mgPart A: Cohort 3: BNT331 20 mg
Any TEAE2112
Any serious TEAE0000
PrimaryPart B: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Any Serious TEAE

Treatment-emergent adverse events are those AEs with an onset on or after the date and time of study treatment or events which were present before treatment, and which worsened after treatment. Serious adverse event (SAE): any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect or was another medically important condition. AE were graded for severity using NCI-CTCAE v5.0, where Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4 - Life-threatening consequences; and Grade 5: Death related to AE.

Time frame:
Up to 120 days after first dose on Day 1
Reported as:
Count of participants · Participants
Part B: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Any Serious TEAE
ParticipantsPart B: Placebo (Combined for Cohorts 4 and 5)Part B: Cohort 4: BNT331 5 mgPart B: Cohort 5: BNT331 20 mg
Any TEAE987
Any serious TEAE000
SecondaryPart A: Serum Concentrations of BNT331 Active Substance

Blood samples were collected to determine the serum concentrations of BNT331 active substance. Geometric Mean and geometric coefficient of variation (GCV) data were reported for the outcome measure.

Time frame:
Pre-dose, 1 hour, 2 hours, 4 hours, 6 hours, 24 hours and 7 days post-dose on Day 1
Reported as:
Geometric mean · nanograms per milliliter
Part A: Serum Concentrations of BNT331 Active Substance
nanograms per milliliterPart A: Cohort 1: BNT331 2 Milligram (mg)Part A: Cohort 2: BNT331 5 mgPart A: Cohort 3: BNT331 20 mg
PredoseNA ± NANA ± NANA ± NA
1 hour Post doseNA ± NANA ± NANA ± NA
2 hour Post doseNA ± NANA ± NANA ± NA
4 hour Post doseNA ± NANA ± NANA ± NA
6 hour Post doseNA ± NANA ± NANA ± NA
24 hour Post doseNA ± NANA ± NANA ± NA
7 days Post doseNA ± NANA ± NANA ± NA
SecondaryPart B: Serum Concentrations of BNT331 Active Substance

Blood samples were collected to determine the serum concentrations of BNT331 active substance. Geometric Mean and coefficient of variation data were reported for the outcome measure.

Time frame:
Pre-dose, At Visit 2 (i.e. Day 6 post dose on Day 1) and at Visit 3 (i.e., Days 21 to 30 post-dose on Day 1)
Reported as:
Geometric mean · nanograms per milliliter
Part B: Serum Concentrations of BNT331 Active Substance
nanograms per milliliterPart B: Cohort 4: BNT331 5 mgPart B: Cohort 5: BNT331 20 mg
Pre-doseNA ± NANA ± NA
Visit 2NA ± NANA ± NA
Visit 3NA ± NANA ± NA
SecondaryPart A: Number of Participants With Qualitative Anti-drug Antibody (ADA) for BNT331 Active Substance in Blood

ADA-positive samples were defined as a sample confirmed to be positive for the presence of reactive antibodies. Positive qualitative ADA for BNT331 active substance in blood were reported in the outcome measure.

Time frame:
At Pre-dose (Baseline), at 7 days post-dose on Day 1
Reported as:
Count of participants · Participants
Part A: Number of Participants With Qualitative Anti-drug Antibody (ADA) for BNT331 Active Substance in Blood
ParticipantsPart A: Cohort 1: BNT331 2 Milligram (mg)Part A: Cohort 2: BNT331 5 mgPart A: Cohort 3: BNT331 20 mg
At Pre-dose (Baseline)000
At 7 days post-dose on Day 1000
SecondaryPart B: Number of Participants With Qualitative Anti-drug Antibody (ADA) for BNT331 Active Substance in Blood

ADA-positive samples were defined as a sample confirmed to be positive for the presence of reactive antibodies. Positive qualitative ADAs for BNT331 active substance in blood were reported in the outcome measure.

Time frame:
At Pre-dose (Baseline), 6 days after the first dose on Day 1, 21 to 30 days after the first dose on Day 1, and 60 days after the first dose on Day 1
Reported as:
Count of participants · Participants
Part B: Number of Participants With Qualitative Anti-drug Antibody (ADA) for BNT331 Active Substance in Blood
ParticipantsPart B: Cohort 4: BNT331 5 mgPart B: Cohort 5: BNT331 20 mg
At Pre-dose (Baseline)00
6 days after the first dose on Day 100
21 to 30 days after the first dose on Day 100
60 days after the first dose on Day 120
SecondaryPart B - Number of Participants With Clinical Cure

Clinical cure was defined as normalization of the vaginal discharge, a negative KOH "Whiff" test, and clue cells \<20% of the total epithelial cells/high power field on microscopic examination of the vaginal fluid. Data for this outcome measure was not planned to be collected and analyzed for Part A.

Time frame:
At 6 days after first dose on Day 1; and 21 to 30 days after the first dose on Day 1
Reported as:
Count of participants · Participants
Part B - Number of Participants With Clinical Cure
ParticipantsPart B: PlaceboPart B: Cohort 4: BNT331 5 mgPart B: Cohort 5: BNT331 20 mg
At 6 days after first dose on Day 19713
21 to 30 days after the first dose on Day 17711
SecondaryPart B: Number of Participants With Nugent Score Cure/Microbiological Cure

Nugent score cure/Microbiological cure was defined as a score of \<4. A Nugent score of 7-10 is indicative of BV, while a score of 4 to 6 is considered intermediate vaginal microbiota and a score of 0 to 3 is considered normal vaginal microbiota. Data for this outcome measure was not planned to be collected and analyzed for Part A.

Time frame:
At 6 days after first dose on Day 1; and 21 to 30 days after the first dose on Day 1
Reported as:
Count of participants · Participants
Part B: Number of Participants With Nugent Score Cure/Microbiological Cure
ParticipantsPart B: PlaceboPart B: Cohort 4: BNT331 5 mgPart B: Cohort 5: BNT331 20 mg
At 6 days after first dose on Day 1333
21 to 30 days after the first dose on Day 1211
SecondaryPart B: Number of Participants (Responders Outcome) Reporting Clinical Cure With a Normal Nugent Score of Less Than (<) 4

Responder outcome was defined as an occurrence of clinical cure with a normal Nugent score (\<4). A Nugent score of 7-10 is indicative of BV, while a score of 4 to 6 is considered intermediate vaginal microbiota and a score of 0 to 3 is considered normal vaginal microbiota. Data for this outcome measure was not planned to be collected and analyzed for Part A.

Time frame:
At 6 days after first dose on Day 1; and 21 to 30 days after the first dose on Day 1
Reported as:
Count of participants · Participants
Part B: Number of Participants (Responders Outcome) Reporting Clinical Cure With a Normal Nugent Score of Less Than (<) 4
ParticipantsPart B: PlaceboPart B: Cohort 4: BNT331 5 mgPart B: Cohort 5: BNT331 20 mg
At 6 days after first dose on Day 1133
21 to 30 days after the first dose on Day 1111

Adverse events

Collected over AE and SAE data were collected up to 7 days post dose on Day 1 for Part A and up to 120 days after first dose on Day 1 for Part B arms. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Placebo (Combined for Cohorts 1, 2 and 3)0/6 (0%)0/6 (0%)2/6 (33.3%)
Part A: Cohort 1: BNT331 2 Milligram (mg)0/6 (0%)0/6 (0%)1/6 (16.7%)
Part A: Cohort 2: BNT331 5 mg0/6 (0%)0/6 (0%)1/6 (16.7%)
Part A: Cohort 3: BNT331 20 mg0/6 (0%)0/6 (0%)2/6 (33.3%)
Part B: Placebo (Combined for Cohorts 4 and 5)0/25 (0%)0/25 (0%)9/25 (36%)
Part B: Cohort 4: BNT331 5 mg0/25 (0%)0/25 (0%)8/25 (32%)
Part B: Cohort 5: BNT331 20 mg0/23 (0%)0/23 (0%)7/23 (30.4%)
Most frequent other events
Showing 10 of 30
Most frequent other events
EventPart A: Placebo (Combined for Cohorts 1, 2 and 3)Part A: Cohort 1: BNT331 2 Milligram (mg)Part A: Cohort 2: BNT331 5 mgPart A: Cohort 3: BNT331 20 mgPart B: Placebo (Combined for Cohorts 4 and 5)Part B: Cohort 4: BNT331 5 mgPart B: Cohort 5: BNT331 20 mg
ConstipationGastrointestinal disorders1/60/60/60/60/250/250/23
DiarrhoeaGastrointestinal disorders0/60/60/61/60/250/250/23
NauseaGastrointestinal disorders0/61/60/60/60/250/250/23
VomitingGastrointestinal disorders0/61/60/60/60/250/250/23
Traumatic painInjury, poisoning and procedural complications0/60/60/61/60/250/250/23
HeadacheNervous system disorders0/61/60/60/60/250/251/23
Micturition urgencyRenal and urinary disorders0/60/61/60/60/250/250/23
Vulvovaginal painReproductive system and breast disorders1/60/60/60/60/250/250/23
Vulvovaginal mycotic infectionInfections and infestations0/60/60/60/63/252/251/23
Abdominal pain lowerGastrointestinal disorders0/60/60/60/61/252/250/23

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Part A: Placebo (Combined for Cohorts 1, 2 and 3)Part A: Cohort 1: BNT331 2 Milligram (mg)Part A: Cohort 2: BNT331 5 mgPart A: Cohort 3: BNT331 20 mgPart B: Placebo (Combined for Cohorts 4 and 5)Part B: Cohort 4: BNT331 5 mgPart B: Cohort 5: BNT331 20 mgTotal
Part A35.7 ± 7.6136.3 ± 10.8236.8 ± 8.4231.8 ± 7.78———35.2 ± 8.41
Part B————35.2 ± 8.0234.4 ± 9.0036.0 ± 8.2935.1 ± 8.36
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Placebo (Combined for Cohorts 1, 2 and 3)Part A: Cohort 1: BNT331 2 Milligram (mg)Part A: Cohort 2: BNT331 5 mgPart A: Cohort 3: BNT331 20 mgPart B: Placebo (Combined for Cohorts 4 and 5)Part B: Cohort 4: BNT331 5 mgPart B: Cohort 5: BNT331 20 mgTotal
Part A — Female6666———24
Part A — Male0000———0
Part B — Female————25252373
Part B — Male————0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Placebo (Combined for Cohorts 1, 2 and 3)Part A: Cohort 1: BNT331 2 Milligram (mg)Part A: Cohort 2: BNT331 5 mgPart A: Cohort 3: BNT331 20 mgPart B: Placebo (Combined for Cohorts 4 and 5)Part B: Cohort 4: BNT331 5 mgPart B: Cohort 5: BNT331 20 mgTotal
Part A — Hispanic or Latino0000———0
Part A — Not Hispanic or Latino6666———24
Part A — Unknown or Not Reported0000———0
Part B — Hispanic or Latino————1225
Part B — Not Hispanic or Latino————24232168
Part B — Unknown or Not Reported————0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: Placebo (Combined for Cohorts 1, 2 and 3)Part A: Cohort 1: BNT331 2 Milligram (mg)Part A: Cohort 2: BNT331 5 mgPart A: Cohort 3: BNT331 20 mgPart B: Placebo (Combined for Cohorts 4 and 5)Part B: Cohort 4: BNT331 5 mgPart B: Cohort 5: BNT331 20 mgTotal
Part A — American Indian or Alaska Native0000———0
Part A — Asian1010———2
Part A — Black or African American1000———1
Part A — Native Hawaiian or Other Pacific Islander0000———0
Part A — White4555———19
Part A — Multiple0001———1
Part A — Other0100———1
Part A — Not reported0000———0
Part A — Unknown0000———0
Part B — American Indian or Alaska Native————0000
Part B — Asian————0000
Part B — Black or African American————19191755
Part B — Native Hawaiian or Other Pacific Islander————0000
Part B — White————54615
Part B — Multiple————1102
Part B — Other————0101
Part B — Not reported————0000
Part B — Unknown————0000
Anti-drug Antibody (ADA) in Blood Results Positive
Anti-drug Antibody (ADA) in Blood Results Positive(Participants)Part A: Placebo (Combined for Cohorts 1, 2 and 3)Part A: Cohort 1: BNT331 2 Milligram (mg)Part A: Cohort 2: BNT331 5 mgPart A: Cohort 3: BNT331 20 mgPart B: Placebo (Combined for Cohorts 4 and 5)Part B: Cohort 4: BNT331 5 mgPart B: Cohort 5: BNT331 20 mgTotal
Part A—000———0
Part B—————000
Nugent Score
Nugent Score(Score on a scale)Part A: Placebo (Combined for Cohorts 1, 2 and 3)Part A: Cohort 1: BNT331 2 Milligram (mg)Part A: Cohort 2: BNT331 5 mgPart A: Cohort 3: BNT331 20 mgPart B: Placebo (Combined for Cohorts 4 and 5)Part B: Cohort 4: BNT331 5 mgPart B: Cohort 5: BNT331 20 mgTotal
Part A0.8 ± 2.040.0 ± 0.000.5 ± 1.220.0 ± 0.00———0.3 ± 1.17
Part B————7.6 ± 3.446.6 ± 3.598.4 ± 2.617.5 ± 3.30
Amsel's Criteria
Amsel's Criteria(Participants)Part A: Placebo (Combined for Cohorts 1, 2 and 3)Part A: Cohort 1: BNT331 2 Milligram (mg)Part A: Cohort 2: BNT331 5 mgPart A: Cohort 3: BNT331 20 mgPart B: Placebo (Combined for Cohorts 4 and 5)Part B: Cohort 4: BNT331 5 mgPart B: Cohort 5: BNT331 20 mgTotal
Part A———————0
Part B————25252373
08

Study locations

6 sites
  • UAB Sexual Health Research Clinic
    Birmingham, Alabama 35294-0007, United States
  • Praetorian Pharmaceutical Research, LLC
    Marrero, Louisiana 70072, United States
  • Southern Clinical Research Associates - Metairie
    Metairie, Louisiana 70001, United States
  • Women Under Study, LLC
    New Orleans, Louisiana 70125, United States
  • Nucleus Network
    Saint Paul, Minnesota 55114, United States
  • Chattanooga Medical Research, LLC
    Chattanooga, Tennessee 37412, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Jul 2025, 12 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2024
First posted
Jun 21, 2024
StartActual
Jul 1, 2024
Primary completionActual
Jul 31, 2025
CompletionActual
Jul 31, 2025
Results first posted
Oct 5, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 5, 2026
Eligibility
13 criteria edited
What changed in the criteria
  • EditedHaveHad given written informed consent by signing and dating the informed consent form (ICF) before initiation of any study-specific procedures.
  • EditedPart A and Part B: At Visit 0 and not expectingexpected to menstruate during Visit 1 and until Visit 3.
  • EditedPart B only: At Visit 0 and Visit 1 and do not expectexpected to menstruate within the next 6 days after Visit 1, until the Early Response Visit (Visit 2).
  • EditedPart A only: AreWere healthy according to screening procedures. Part B only: Participants suffering from BV but who arewere otherwise healthy in the clinical judgement of the investigator.
  • EditedNote: Participants with pre-existing stable disease (e.g., obesity, hypertension, etc.), defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 90 days before Visit 0, can bewere included.
  • EditedA positive 10% potassium hydroxide (KOH) Whiff test.
  • EditedHaveHad genital lesions, including active herpes simplex virus or syphilitic lesions, or other vaginal or vulvar conditions.
  • EditedPart A only: HaveHad active STI.
  • EditedAreWere using a Copper intrauterine device, or any vaginal hormonal products (including NuvaRing®) as a form of contraception.
  • EditedHasHad any history of allergies, hypersensitivities, or intolerance to the study treatments including any excipients thereof.
  • EditedHasHad any history of an abnormal Pap smear which required cervical biopsy and/or cervical cauterization within 6 months of Visit 1.
  • EditedHasHad any condition including psychiatric illnesses that could interfere with their ability to understand or comply with the requirements of the study as determined by the investigator.
  • EditedVulnerable individuals, i.e., arewere individuals whose willingness to participate in a clinical study may bewas unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate. This includes all sponsor, study site, or third party (e.g., CROClinical Research Organization, vendor) personnel directly involved in the conduct of the study and their family members or dependents, as well as all study site personnel otherwise supervised by the investigator.
Oct 5, 2026
Interventions
Arms added: Part A: Placebo (Combined for Cohorts 1, 2 and 3)·Part A: Cohort 1: BNT331 2 Milligram (mg)·Part A: Cohort 2: BNT331 5 mg·Part A: Cohort 3: BNT331 20 mg·Part B: Placebo (Combined for Cohorts 4 and 5)·and 2 more
All 7

Part A: Placebo (Combined for Cohorts 1, 2 and 3) · Part A: Cohort 1: BNT331 2 Milligram (mg) · Part A: Cohort 2: BNT331 5 mg · Part A: Cohort 3: BNT331 20 mg · Part B: Placebo (Combined for Cohorts 4 and 5) · Part B: Cohort 4: BNT331 5 mg · Part B: Cohort 5: BNT331 20 mg

; arms removed: BNT331 - Part A·Placebo - Part A·BNT331 - Part B Dose 1·BNT331 - Part B Dose 2·Placebo - Part B
Oct 5, 2026
Primary outcomes
2 added, 4 removed
What changed in the outcomes
  • AddedPart A: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Any Serious TEAETime frame: Up to 7 days post dose on Day 1
  • AddedPart B: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Any Serious TEAETime frame: Up to 120 days after first dose on Day 1
  • RemovedPart A - Percentage of participants with adverse events (AEs) with onset after first treatment dose and until 7 days post-doseTime frame: from first dose of study treatment up to 7 days post-dose
  • RemovedPart B - Percentage of participants with adverse events (AEs) with onset after first treatment dose and until 120 days after the first doseTime frame: from first dose of study treatment up to 120 days after first dose
  • RemovedPart A - Percentage of participants with serious adverse events (SAEs) with onset after first treatment dose and until 7 days post-doseTime frame: from first dose of study treatment up to 7 days post-dose
  • RemovedPart B - Percentage of participants with SAEs with onset after first treatment dose and until 120 days after the first doseTime frame: from first dose of study treatment up to 120 days after first dose
Oct 5, 2026
Documents
Secondary outcomes
7 edited
What changed in the outcomes
  • EditedPart A -: Serum concentrationsConcentrations of BNT331 active substance at pre-specified timepointsActive SubstanceTime frame: from pre-dose up to 12 days post-dose → Pre-dose, 1 hour, 2 hours, 4 hours, 6 hours, 24 hours and 7 days post-dose on Day 1
  • EditedPart B -: Serum concentrationsConcentrations of BNT331 active substance at pre-specified timepointsActive SubstanceTime frame: from pre-dose up to 30 days after first dose → Pre-dose, At Visit 2 (i.e. Day 6 post dose on Day 1) and at Visit 3 (i.e., Days 21 to 30 post-dose on Day 1)
  • EditedPart A -: Number of Participants With Qualitative Anti-drug antibodyAntibody (ADA) prevalence and change of binding titers againstfor BNT331 active substanceActive Substance in blood before study treatment and at 7 days post-doseBloodTime frame: from pre-dose up to 7 days post-dose → At Pre-dose (Baseline), at 7 days post-dose on Day 1
  • EditedPart B - Number of participants with clinical cureParticipants With Clinical CureTime frame: At 6 days after first dose and 21 to 30 days after the first dose → At 6 days after first dose on Day 1; and 21 to 30 days after the first dose on Day 1
  • EditedPart B -: Number of participants withParticipants With Nugent score cureScore Cure/Microbiological cureCureTime frame: At 6 days after first dose and 21 to 30 days after the first dose → At 6 days after first dose on Day 1; and 21 to 30 days after the first dose on Day 1
  • EditedPart B - Responder outcome -: Number of participants with clinical cure and normalParticipants (Responders Outcome) Reporting Clinical Cure With a Normal Nugent scoreScore of Less Than (<) 4Time frame: At 6 days after first dose and 21 to 30 days after the first dose → At 6 days after first dose on Day 1; and 21 to 30 days after the first dose on Day 1
  • ChangedBefore Part B - ADA prevalence and change of binding titers against BNT331 active substance in blood before study treatment and at 6 days after the first dose, 21 to 30 days after the first dose, and 120 days after the first doseNow Part B: Number of Participants With Qualitative Anti-drug Antibody (ADA) for BNT331 Active Substance in BloodTime frame: from pre-dose up to 120 days after first dose → At Pre-dose (Baseline), 6 days after the first dose on Day 1, 21 to 30 days after the first dose on Day 1, and 60 days after the first dose on Day 1
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Results posted
    Eligibility 13 criteria edited
    What changed in the criteria
    • EditedHaveHad given written informed consent by signing and dating the informed consent form (ICF) before initiation of any study-specific procedures.
    • EditedPart A and Part B: At Visit 0 and not expectingexpected to menstruate during Visit 1 and until Visit 3.
    • EditedPart B only: At Visit 0 and Visit 1 and do not expectexpected to menstruate within the next 6 days after Visit 1, until the Early Response Visit (Visit 2).
    • EditedPart A only: AreWere healthy according to screening procedures. Part B only: Participants suffering from BV but who arewere otherwise healthy in the clinical judgement of the investigator.
    • EditedNote: Participants with pre-existing stable disease (e.g., obesity, hypertension, etc.), defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 90 days before Visit 0, can bewere included.
    • EditedA positive 10% potassium hydroxide (KOH) Whiff test.
    • EditedHaveHad genital lesions, including active herpes simplex virus or syphilitic lesions, or other vaginal or vulvar conditions.
    • EditedPart A only: HaveHad active STI.
    • EditedAreWere using a Copper intrauterine device, or any vaginal hormonal products (including NuvaRing®) as a form of contraception.
    • EditedHasHad any history of allergies, hypersensitivities, or intolerance to the study treatments including any excipients thereof.
    • EditedHasHad any history of an abnormal Pap smear which required cervical biopsy and/or cervical cauterization within 6 months of Visit 1.
    • EditedHasHad any condition including psychiatric illnesses that could interfere with their ability to understand or comply with the requirements of the study as determined by the investigator.
    • EditedVulnerable individuals, i.e., arewere individuals whose willingness to participate in a clinical study may bewas unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate. This includes all sponsor, study site, or third party (e.g., CROClinical Research Organization, vendor) personnel directly involved in the conduct of the study and their family members or dependents, as well as all study site personnel otherwise supervised by the investigator.
    Primary outcomes 2 added, 4 removed
    What changed in the outcomes
    • AddedPart A: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Any Serious TEAETime frame: Up to 7 days post dose on Day 1
    • AddedPart B: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Any Serious TEAETime frame: Up to 120 days after first dose on Day 1
    • RemovedPart A - Percentage of participants with adverse events (AEs) with onset after first treatment dose and until 7 days post-doseTime frame: from first dose of study treatment up to 7 days post-dose
    • RemovedPart B - Percentage of participants with adverse events (AEs) with onset after first treatment dose and until 120 days after the first doseTime frame: from first dose of study treatment up to 120 days after first dose
    • RemovedPart A - Percentage of participants with serious adverse events (SAEs) with onset after first treatment dose and until 7 days post-doseTime frame: from first dose of study treatment up to 7 days post-dose
    • RemovedPart B - Percentage of participants with SAEs with onset after first treatment dose and until 120 days after the first doseTime frame: from first dose of study treatment up to 120 days after first dose
    Secondary outcomes 7 edited
    What changed in the outcomes
    • EditedPart A -: Serum concentrationsConcentrations of BNT331 active substance at pre-specified timepointsActive SubstanceTime frame: from pre-dose up to 12 days post-dose → Pre-dose, 1 hour, 2 hours, 4 hours, 6 hours, 24 hours and 7 days post-dose on Day 1
    • EditedPart B -: Serum concentrationsConcentrations of BNT331 active substance at pre-specified timepointsActive SubstanceTime frame: from pre-dose up to 30 days after first dose → Pre-dose, At Visit 2 (i.e. Day 6 post dose on Day 1) and at Visit 3 (i.e., Days 21 to 30 post-dose on Day 1)
    • EditedPart A -: Number of Participants With Qualitative Anti-drug antibodyAntibody (ADA) prevalence and change of binding titers againstfor BNT331 active substanceActive Substance in blood before study treatment and at 7 days post-doseBloodTime frame: from pre-dose up to 7 days post-dose → At Pre-dose (Baseline), at 7 days post-dose on Day 1
    • EditedPart B - Number of participants with clinical cureParticipants With Clinical CureTime frame: At 6 days after first dose and 21 to 30 days after the first dose → At 6 days after first dose on Day 1; and 21 to 30 days after the first dose on Day 1
    • EditedPart B -: Number of participants withParticipants With Nugent score cureScore Cure/Microbiological cureCureTime frame: At 6 days after first dose and 21 to 30 days after the first dose → At 6 days after first dose on Day 1; and 21 to 30 days after the first dose on Day 1
    • EditedPart B - Responder outcome -: Number of participants with clinical cure and normalParticipants (Responders Outcome) Reporting Clinical Cure With a Normal Nugent scoreScore of Less Than (<) 4Time frame: At 6 days after first dose and 21 to 30 days after the first dose → At 6 days after first dose on Day 1; and 21 to 30 days after the first dose on Day 1
    • ChangedBefore Part B - ADA prevalence and change of binding titers against BNT331 active substance in blood before study treatment and at 6 days after the first dose, 21 to 30 days after the first dose, and 120 days after the first doseNow Part B: Number of Participants With Qualitative Anti-drug Antibody (ADA) for BNT331 Active Substance in BloodTime frame: from pre-dose up to 120 days after first dose → At Pre-dose (Baseline), 6 days after the first dose on Day 1, 21 to 30 days after the first dose on Day 1, and 60 days after the first dose on Day 1
    Interventions Arms added: Part A: Placebo (Combined for Cohorts 1, 2 and 3)·Part A: Cohort 1: BNT331 2 Milligram (mg)·Part A: Cohort 2: BNT331 5 mg·Part A: Cohort 3: BNT331 20 mg·Part B: Placebo (Combined for Cohorts 4 and 5)·and 2 more
    All 7

    Part A: Placebo (Combined for Cohorts 1, 2 and 3) · Part A: Cohort 1: BNT331 2 Milligram (mg) · Part A: Cohort 2: BNT331 5 mg · Part A: Cohort 3: BNT331 20 mg · Part B: Placebo (Combined for Cohorts 4 and 5) · Part B: Cohort 4: BNT331 5 mg · Part B: Cohort 5: BNT331 20 mg

    ; arms removed: BNT331 - Part A·Placebo - Part A·BNT331 - Part B Dose 1·BNT331 - Part B Dose 2·Placebo - Part B
    + 3 other changes: index terms, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06469164
Lead sponsor
BioNTech SE
Responsible party
Sponsor
First posted
Jun 21, 2024
Start date
Jul 1, 2024
Primary completion
Jul 31, 2025
Completion
Jul 31, 2025
Results posted
Oct 5, 2026
Last update
Oct 5, 2026

Study contacts

BioNTech Responsible Person
study director · BioNTech SE

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion